.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Emerging research suggests that METTL7B in Papillary Thyroid Carcinoma plays a critical role in metabolic reprogramming and tumor malignancy. Methyltransferase-like protein 7B (METTL7B) is a member of the methyltransferase-like family that significantly influences cancer cell behavior. Researchers recently identified that METTL7B is markedly upregulated in clinical tissues of patients with papillary thyroid carcinoma (PTC). Furthermore, this elevated expression correlates strongly with advanced clinical stages and the presence of lymph node metastasis. Consequently, identifying the molecular pathways involved is essential for developing targeted therapies.
The study elucidates that METTL7B operates through the USP28/HIF-1α axis to facilitate tumor growth. Specifically, METTL7B interacts with ubiquitin-specific protease 28 (USP28) to enhance its binding with hypoxia-inducible factor 1α (HIF-1α). Therefore, this interaction prevents the ubiquitination and subsequent degradation of HIF-1α. Stabilized levels of HIF-1α promote aerobic glycolysis, also known as the Warburg effect. This metabolic shift increases glucose uptake and lactate production within the tumor microenvironment. Additionally, laboratory experiments demonstrated that knockdown of METTL7B significantly reduces the proliferation and clonogenic potential of PTC cells. Moreover, transcriptomic sequencing confirmed that METTL7B-mediated regulation of metabolic pathways is a primary driver of the malignant phenotype.
Metabolic reprogramming represents a hallmark of cancer progression that allows cells to thrive under hypoxic conditions. In the context of METTL7B in Papillary Thyroid Carcinoma, the stabilization of the USP28/HIF-1α axis provides a survival advantage to malignant cells. Clinicians observe that tumors with high METTL7B expression exhibit more aggressive behaviors compared to those with low expression. In summary, the METTL7B/USP28/HIF-1α regulatory axis offers a promising biomarker for risk stratification. Furthermore, targeting this axis may provide a novel therapeutic strategy for patients with treatment-resistant or advanced thyroid malignancies.
High expression of METTL7B correlates with larger tumor sizes, increased lymph node metastasis, and more advanced TNM staging. It serves as a marker for metabolic reprogramming and heightened malignancy in thyroid tissues.
METTL7B recruits USP28 to stabilize the HIF-1α protein, which prevents its degradation. This process increases glycolytic activity, providing the energy and building blocks required for rapid cancer cell proliferation and survival.
Yes, targeting METTL7B or its downstream partners like USP28 could potentially inhibit glycolysis and suppress the malignant progression of papillary thyroid carcinoma, offering a new avenue for precision medicine.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References
Xu F et al. [Methyltransferase-like protein 7B promotes glycolysis and malignant progression in papillary thyroid carcinoma via the USP28/HIF-1α axis]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2026 Jun 22. doi: 10.3724/zdxbyxb-2025-0822. PMID: 42332350.
Yang J et al. METTL7B Is Required for Cancer Cell Proliferation and Tumorigenesis in Non-Small Cell Lung Cancer. Front Oncol. 2020 Feb 27;10:178.
Kim J et al. HIF-1α/YAP Signaling Rewrites Glucose/Iodine Metabolism Program to Promote Papillary Thyroid Cancer Progression. Int J Biol Sci. 2023;19(1):15-32.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Recent research highlights METTL7B's role in driving papillary thyroid carcinoma (PTC) progression. By interacting with USP28 to stabilize HIF-1α, METTL7B enhances glycolytic activity and tumor growth, presenting a potential therapeutic target for advanced PTC cases.
2 months ago
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
Last week
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
4 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
Last week
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
4 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
Last week
